A Feasibility Study of Tamoxifen Prevention of Breast Cancer in Hodgkin's Disease Survivors
- Patients will receive tamoxifen orally once daily to be taken at home for 1 year. They
will be asked to complete a daily drug log to keep track of the pills taken or missed.
- Patients will also be asked to give a blood/DNA sample which will be stored for
possible further testing for the presence of cancer related genes that are known nor or
discovered in the future.
- Patients will also receive a mammogram that will be reviewed by study officials.
- Side effects will be monitored every 2 months for one year, between visits to the
- A follow-up visit will be conducted at the 6 month mark and includes a physical exam,
blood work, health and wellness surveys)
- A follow-up visit will be performed at the 1 year mark and includes a mammogram,
gynecological exam, physical exam, blood work, health and wellness surveys.
- Patients active participation will be for 1 year. However, tamoxifen has been shown to
be effective after a 5-year course in other women at increased risk for breast cancer,
the patient may decide to stay on tamoxifen for 4 additional years.
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
To determine the feasibility of a randomized trial testing the effectiveness of tamoxifen in reducing the risk of radiogenic breast cancer.
Judy Garber, MD, MPH
Dana-Farber Cancer Institute
United States: Institutional Review Board
|Dana-Farber Cancer Institute||Boston, Massachusetts 02115|
|Massachusetts General Hospital||Boston, Massachusetts 02114-2617|